Literature DB >> 30645722

Risk Factors for Relapse of Hyperglycemia after Laparoscopic Roux-en-Y Gastric Bypass in T2DM Obese Patients: a 5-Year Follow-Up of 24 Cases.

Wang Xiaosong1, Su Chongyu1, Shen Xuqi1, Yu Peiwu2, Zhao Yongliang3.   

Abstract

OBJECTIVES: To explore the risk factors for relapse of hyperglycemia in obese patients with type II diabetes mellitus (T2DM) who received laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery.
METHODS: A retrospective analysis was performed on all obese patients with T2DM who underwent a LRYGB during the period 2011-2013. Demographics, preoperative body mass index (BMI), preoperative glycated hemoglobin A1c (HbA1c), adherence to lifestyle intervention, preoperative medication of insulin, and the time interval between surgery and diagnosis of T2DM were investigated and compared.
RESULTS: A total of 24 patients were included in our study. The median age was 45.5 years, the median BMI was 29.9 kg/m2, and the median HbA1c was 7.9%. Out of 24 patients, 54.2% (13/24) experienced a relapse of hyperglycemia. The 1-year, 3-year, and 5-year relapse rates were 4.2%, 12.5%, and 50.0%, respectively. The preoperative HbA1c level, C-peptide (2 h) level, and C-peptide (3 h) level were identified as independent variables for the relapse of hyperglycemia (8.11 ± 0.48 vs 7.72 ± 0.37 kg/m2, p = 0.036; 4.35 ± 1.46 vs 7.13 ± 4.10 ng/ml, p = 0.032; 3.76 ± 0.61 vs 5.99 ± 3.39 ng/ml, p = 0.029). Lifestyle intervention could reduce the hyperglycemia relapse rate (66.7 vs 41.7%) after LRYGB surgery.
CONCLUSIONS: The preoperative HbA1c level and C-peptide level at surgery have an important significance in predicting the relapse of hyperglycemia after LRYGB surgery; lifestyle intervention is crucial for these patients.

Entities:  

Keywords:  LRYGB; Obesity; Recurrence of T2DM

Mesh:

Substances:

Year:  2019        PMID: 30645722     DOI: 10.1007/s11695-018-03656-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  15 in total

Review 1.  The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus.

Authors:  Francesco Rubino; Lee M Kaplan; Philip R Schauer; David E Cummings
Journal:  Ann Surg       Date:  2010-03       Impact factor: 12.969

2.  Bariatric surgery versus intensive medical therapy in obese patients with diabetes.

Authors:  Philip R Schauer; Sangeeta R Kashyap; Kathy Wolski; Stacy A Brethauer; John P Kirwan; Claire E Pothier; Susan Thomas; Beth Abood; Steven E Nissen; Deepak L Bhatt
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

3.  Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity.

Authors:  Tom C Hall; Mike G C Pellen; Peter C Sedman; Prashant K Jain
Journal:  Obes Surg       Date:  2010-09       Impact factor: 4.129

4.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

Authors:  N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda
Journal:  Diabetes Res Clin Pract       Date:  2018-02-26       Impact factor: 5.602

5.  Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass.

Authors:  Silas M Chikunguwo; Luke G Wolfe; Patricia Dodson; Jill G Meador; Nancy Baugh; John N Clore; John M Kellum; James W Maher
Journal:  Surg Obes Relat Dis       Date:  2009-11-10       Impact factor: 4.734

6.  Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up.

Authors:  Mary DiGiorgi; Daniel J Rosen; Jenny J Choi; Luca Milone; Beth Schrope; Lorraine Olivero-Rivera; Nancy Restuccia; Sara Yuen; McKenzie Fisk; William B Inabnet; Marc Bessler
Journal:  Surg Obes Relat Dis       Date:  2009-10-29       Impact factor: 4.734

7.  Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.

Authors:  Geltrude Mingrone; Simona Panunzi; Andrea De Gaetano; Caterina Guidone; Amerigo Iaconelli; Giuseppe Nanni; Marco Castagneto; Stefan Bornstein; Francesco Rubino
Journal:  Lancet       Date:  2015-09-05       Impact factor: 79.321

8.  Effect of sleeve gastrectomy on patients with diabetes mellitus.

Authors:  Raul Rosenthal; Xinxiang Li; Szomstein Samuel; Pedro Martinez; Chengzhu Zheng
Journal:  Surg Obes Relat Dis       Date:  2008-11-18       Impact factor: 4.734

9.  Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders.

Authors:  D J Pournaras; E T Aasheim; T T Søvik; R Andrews; D Mahon; R Welbourn; T Olbers; C W le Roux
Journal:  Br J Surg       Date:  2011-10-21       Impact factor: 6.939

10.  Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes.

Authors:  Dimitrios J Pournaras; Alan Osborne; Simon C Hawkins; Royce P Vincent; David Mahon; Paul Ewings; Mohammad A Ghatei; Stephen R Bloom; Richard Welbourn; Carel W le Roux
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

View more
  2 in total

Review 1.  Meta-analysis of Long-Term Relapse Rate of Type 2 Diabetes Following Initial Remission After Roux-en-Y Gastric Bypass.

Authors:  Zhiqing Yu; Peiwu Li; Peirong Li; Haidan Zhang; Youcheng Zhang
Journal:  Obes Surg       Date:  2021-09-10       Impact factor: 3.479

2.  Metabolic surgery in China: present and future.

Authors:  Yinfang Tu; Yuqian Bao; Pin Zhang
Journal:  J Mol Cell Biol       Date:  2021-07-07       Impact factor: 6.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.